Skip to content

Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases

Observational, Follow-up Study of Adaptive Optics Retinal Imaging in Controls and During Retinal or General Diseases

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01546181
Acronym
iPhot
Enrollment
256
Registered
2012-03-07
Start date
2010-10-31
Completion date
2017-06-15
Last updated
2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-related Macular Degeneration, Arterial Hypertension, Diabetes, Retinal Dystrophies, Toxic Retinopathies, Traumatic Retinopathy

Keywords

photoreceptors, retinal pigment epithelium, adaptive optics

Brief summary

Using an adaptive optics imaging device, retinal structures are observed in healthy and diseased subjects.

Detailed description

Most cases of severe visual loss in developed countries are due to retinal diseases affecting a specialized class of neurons, the photoreceptors. Currently available systems for retinal imaging in humans do not allow neuronal imaging at the cellular level, which is crucial to understand, diagnose and monitor retinal diseases. In recent years, adaptive optics (AO) fundus imaging has proven its capability to image individual photoreceptor cells in the human retina. This technology is now reaching technical maturation. A prototypic AO system (manufactured by Imagine Eyes) is currently in operation in a clinical setting (Clinical Investigation Center 503) and has proven its reliability to monitor single photoreceptors over time. Yet, the clinical evaluation of AO imaging is still in its infancy, and biomarkers issued from AO imaging have not been validated. The goal of the iPhot project is thus to optimize the process of AO imaging (from the implementation of novel technical solution to image processing and data analysis) in order to obtain morphological, quantitative and longitudinal information concerning retinal microstructures in humans. For instance, we will aim at detecting early photoreceptor damage during retinal dystrophies.

Interventions

None listed

Sponsors

Institut National de la Santé Et de la Recherche Médicale, France
Lead SponsorOTHER_GOV

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
10 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* over 10 years old

Exclusion criteria

* ocular media opacities, unstable fixation

Design outcomes

Primary

MeasureTime frameDescription
photoreceptor density01/12/2014the variations of the density of photoreceptors over time will be evaluated

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 23, 2026